Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2025-2745

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Blood (2025) 146 (Supplement 1): 5330.

https://doi.org/10.1182/blood-2025-5330

Published: 2025

Journal Articles

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

Amirsaman Ashtari, Jurik Mutter, Benoit Tessoulin, Cedric Rossi, Jan Boegeholz, Jordan Goldstein, Magdalena Klanova, Julia Kuehn, Stefan Alig, Joseph Schroers-Martin, Chih Long Liu, Mari Olsen, Xiaoman Kang, Marek Trneny, Steven Le Gouill, Maximilian Diehn, Mohammad Shahrokh Esfahani, Ash Alizadeh

Blood (2025) 146 (Supplement 1): 1789.

https://doi.org/10.1182/blood-2025-1789

Published: 2025

Journal Articles

Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma

Shengqin Su, Ajay Subramanian, Timothy Flerlage, Jamie Flerlage, Cedric Rossi, Stefan Alig, Sheren Younes, Oscar Silva, Sandra Luna-Fineman, Natalie Park, Troy Noordenbos, Joseph Schroers-Martin, Everett Moding, Richard Hoppe, Ranjana Advani, Yasodha Natkunam, Ash Alizadeh, Michael Binkley

Blood (2025) 146 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2025-1783

Published: 2025

Journal Articles

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Tristan Robert-Van Houtteghem, Marguerite Fournier, Fabrice Jardin, Pierre Feugier, François Lemonnier, Loic Ysebaert, Franck Morschhauser, Laure Lebras, Cedric Rossi, Vincent Ribrag, Catherine Thieblemont, Aurelien Belot, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2025-4495

Published: 2025

Journal Articles

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Blood (2025) 146 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2025-1019

Published: 2025

Journal Articles

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

Blood (2025) 146 (Supplement 1): 1853.

https://doi.org/10.1182/blood-2025-1853

Published: 2025

Journal Articles

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Blood (2025) 146 (Supplement 1): 129.

https://doi.org/10.1182/blood-2025-129

Published: 2025

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Blood (2025) 146 (Supplement 1): 956.

https://doi.org/10.1182/blood-2025-956

Published: 2025

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Jan Boegeholz, Cedric Rossi, Jordan S Goldstein, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph G. Schroers-Martin, Chih Long Liu, Mari Olsen, Xiaoman Kang, Feng Tian, David Kurtz, Marc Andre, Luc-Matthieu Fornecker, Olivier Casasnovas, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 565.

https://doi.org/10.1182/blood-2024-201877

Published: 2024

Journal Articles

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Yassine Al Tabaa, Xavier Pallard, Loic Ysebaert, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Guillaume Cartron, Catherine Thieblemont, Didier Blaise, Cedric Rossi, Francoise Kraeber-Bodere, Benoit Tessoulin, Fabien Le Bras, Olivier Hermine, Emelie Van Zele, Vivien Dupont, Romain Ricci

Blood (2024) 144 (Supplement 1): 7131.

https://doi.org/10.1182/blood-2024-200968

Published: 2024

Journal Articles

Outcomes of Patients Treated with Consolidative Brentuximab Vedotin after Transplant for Hodgkin Lymphoma at High Risk of Progression or Relapse: An Innovative Comparative Analysis Based on Propensity Score Weighting from Patients Included in 4 Lysa-Cohorts

Amira Marouf, Cedric Rossi, Tesla Murairi, Fanny Cherblanc, Loic Chartier, Hervé Ghesquieres, Bénédicte Deau Fischer

Blood (2024) 144 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2024-209608

Published: 2024

Journal Articles

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Benoit Tessoulin, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Cedric Rossi, Caroline Milin, Ludovic Fouillet, Charles Herbaux, Emmanuelle Tchernonog, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2024-206778

Published: 2024

Journal Articles

Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Shengqin Su, Ajay Subramanian, Timothy Flerlage, Jamie E. Flerlage, Cedric Rossi, Troy Noordenbos, Joseph G. Schroers-Martin, Everett J. Moding, Richard T. Hoppe, Ranjana H. Advani, Yasodha Natkunam, Ash A. Alizadeh, Michael S. Binkley

Blood (2024) 144 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2024-212013

Published: 2024

Journal Articles

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Blood (2024) 144 (Supplement 1): 454.

https://doi.org/10.1182/blood-2024-206518

Published: 2024

Journal Articles

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Blood (2024) 144 (Supplement 1): 853.

https://doi.org/10.1182/blood-2024-201644

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling

Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA

Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group

Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Outcomes of Patients Treated with Consolidative Brentuximab Vedotin after Transplant for Hodgkin Lymphoma at High Risk of Progression or Relapse: An Innovative Comparative Analysis Based on Propensity Score Weighting from Patients Included in 4 Lysa-Cohorts

5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial

Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only